Neuroscience
Intravenous Immunoglobulin
100%
Neuropathy
93%
Guillain-Barre Syndrome
73%
Randomized Controlled Trial
52%
Blood Plasma
45%
Placebo
36%
Interferon Beta 1a
34%
T Cell
33%
Nervous System Disorder
22%
Beta Interferon
20%
Immunosuppressive Drug
18%
Azathioprine
17%
Neuromuscular Disorder
16%
Neuritis
15%
CD8
14%
Brain-Derived Neurotrophic Factor
14%
Peripheral Nerve
14%
Sural Nerve
11%
Interferon
11%
Immunoglobulin M
10%
Axon
10%
Methotrexate
9%
Magnetic Resonance Imaging
9%
Paraprotein
9%
Valerian
8%
Glycolipid
8%
Nerve Block
8%
Nervous System Regeneration
8%
Blood Nerve Barrier
8%
Peripheral Myelin Protein 22
8%
Epitope
8%
Matrix Metalloproteinase
8%
Polyneuropathy
7%
Prednisolone
7%
Neurofilament
7%
Multiple Sclerosis
7%
Myelin Associated Glycoprotein
7%
Myelin Oligodendrocyte Glycoprotein
7%
Recombinant Beta Interferon
7%
Oligodendrocyte Myelin Glycoprotein
7%
Neurofibromatosis Type 1
7%
Mycophenolic Acid
7%
Human Immunoglobulin
7%
Lymphocyte
7%
Immunotherapy
7%
Primary Progressive Multiple Sclerosis
7%
2-Deoxy-D-Glucose
7%
positron emission tomographic scan
7%
Apolipoprotein E
7%
Secondary Progressive Multiple Sclerosis
7%
Medicine and Dentistry
Immunoglobulin
68%
Neuropathy
58%
Polyradiculoneuropathy
55%
Placebo
31%
Guillain-Barré Syndrome
30%
Plasma Exchange
27%
Randomized Controlled Trial
25%
Beta1a Interferon
22%
Neurologic Disease
19%
Systematic Review
18%
Multifocal Motor Neuropathy
14%
Neurofibromatosis Type I
14%
Fluorodeoxyglucose
14%
Positron Emission Tomography
14%
Immunotherapy
14%
Nerve Block
11%
Quality of Life
11%
Nervous System Disorder
11%
Nerve Biopsy
10%
Sural Nerve
10%
Autoimmunity
9%
Peripheral Nerve
9%
Neuromuscular Disease
9%
Beta Interferon
8%
Infection
8%
Polyneuropathy
8%
Plexiform Neurofibroma
8%
Malignant Peripheral Nerve Sheath Tumor
8%
Immunoabsorption
8%
Infusion
8%
Neurology
8%
Malignant Neoplasm
8%
Bell's Palsy
7%
Health Care Provider
7%
Health Care
7%
Cohort Effect
7%
Prospective Study
7%
Biopsy Technique
7%
Dyspnea
7%
COVID-19
7%
Post-COVID-19
7%
Chronic Inflammatory Demyelinating Polyneuropathy
7%
Recombinant Beta Interferon
7%
Lymphocyte
7%
Disease
7%
Short Form 36
7%
Clinical Research
7%
DeJerine-Sottas Disease
7%
Disease Activity
7%
Neoplasm
7%
Pharmacology, Toxicology and Pharmaceutical Science
Immunoglobulin
89%
Polyradiculoneuropathy
63%
Placebo
48%
Neuropathy
44%
Randomized Controlled Trial
44%
Beta1a Interferon
40%
Guillain Barre Syndrome
34%
Demyelinating Neuropathy
22%
Diseases
21%
Motor Neuropathy
18%
Beta Interferon
13%
Tolerability
11%
Adverse Event
10%
Paraprotein
9%
Syndrome
9%
Multiple Sclerosis
9%
Immunosuppressive Agent
8%
Haemophilus influenzae
7%
Neurologic Disease
7%
Immunoglobulin M
7%
Recombinant Beta Interferon
7%
Prednisolone
7%
Mycophenolic Acid
7%
Immunotherapy
7%
Brain Derived Neurotrophic Factor
7%
Azathioprine
7%
Recurrence Risk
6%
Prevalence
6%
Neuromuscular Disease
5%
Weakness
5%
Methotrexate
5%
Octanoic Acid
5%
Base
5%